Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients

Código QR

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients

Elisna Syahruddin,1,2 Laksmi Wulandari,3 Nunuk Sri Muktiati,4 Ana Rima,5 Noni Soeroso,6 Sabrina Ermayanti,7 Michael Levi,8 Heriawaty Hidajat,2 Grace Widjajahakim,8 Ahmad Rusdan Handoyo Utomo9 1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia; 2Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, Levi M, Hidajat H, Widjajahakim G, Utomo ARH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	EGFR mutations Lung cancer treatment naive T790M Tyrosine Kinase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/416da6b05a494d97b52271f2dbf78404
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
por: Tran PN, et al.
Publicado: (2016)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner SJ, et al.
Publicado: (2017)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
por: YingYing He, et al.
Publicado: (2021)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Kazutaka Fujita, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko B, et al.
Publicado: (2017)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
por: Alessandro Pancrazzi, et al.
Publicado: (2021)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Reid Oldenburg, MD, PhD, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy
por: Fan Chen, et al.
Publicado: (2021)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli,Meysam, et al.
Publicado: (2019)

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs
por: Louise Pinet, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Mably on Esteem, Republicanism, and the Question of Human Corruption
por: Andreas Blank
Publicado: (2021)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles
por: Tsai WH, et al.
Publicado: (2018)

A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization
por: Kola Srinivas NS, et al.
Publicado: (2016)

Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
por: Masykura N, et al.
Publicado: (2019)

Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
por: Nayanendu Saha, et al.
Publicado: (2022)

Diffusion Reflection Method for Early Detection of Oral Squamous Cell Carcinoma Specifically Targeted by Circulating Gold-Nanorods Bio-Conjugated to Anti-Epidermal Growth Factor Receptor
por: Sudri S, et al.
Publicado: (2021)

Acta Nº874
por: Banco Central de Chile
Publicado: (2019)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)

High glucose levels promote the proliferation of breast cancer cells through GTPases
por: Hou Y, et al.
Publicado: (2017)

Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil
por: Silva Rocha F, et al.
Publicado: (2021)

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
por: Rashid,Mohammad, et al.
Publicado: (2020)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
por: Jeon-Soo Lee, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti F, et al.
Publicado: (2019)